

Amendments to the Claims

The following Listing of Claims shows the claims as currently amended, and will replace all previous versions in the subject application:

LISTING OF CLAIMS

5 Claims 1-52 (canceled).

53 (previously presented). A compressed, layered pharmaceutical dosage form comprising
a first segment comprising a composition containing an effective amount of one or more drugs,
and

10 a second segment contacting said first segment, said second segment comprising an immediate
release composition substantially free of drug, said second segment forming an outer segment of said
dosage form and providing a breaking segment for breaking through said second segment without
substantial consequent breakage of the first segment, wherein said dosage form comprises a score greater
than 50% through the maximum height of one of said first or second segments.

15 54 (previously presented). A compressed, layered pharmaceutical dosage form having its height
greater than its width and configured as

a first segment comprising a composition containing an effective amount of one or more drugs,
and

at least one additional segment comprising a composition containing an effective amount of a
drug or drugs, and

20 a second segment contacting said first segment, said second segment comprising an immediate
release composition substantially free of drug and forming an inner inactive segment that is adjacent
above and below said first and said additional segment,

wherein the compositions of said first and said additional segment and the drug or drugs contained in said
compositions are physically and chemically compatible with one another, and

25 wherein the terms "height" and "width" and "above" and "below" refer to the position of said dosage
form in a tablet die after tablet compression has been completed but before said tablet has been ejected
from said die.

55 (previously presented). A compressed, layered pharmaceutical dosage form having its height
greater than its width and configured as

30 a first segment comprising a composition containing an effective amount of one or more drugs,
and

at least one additional segment comprising a composition containing an effective amount of a drug or drugs, and

a second segment contacting said first segment, said second segment comprising an immediate release composition substantially free of drug and forming an inner inactive segment that is adjacent

above and below said first and said additional segment,

wherein said dosage form

- i) lacks a semi-permeable membrane coating,
- ii) lacks an osmotically active component to effect intrinsic altered release, or
- iii) lacks a drug over-coating,

wherein the terms “height” and “width” and “above” and “below” refer to the position of said dosage form in a tablet die after tablet compression has been completed but before said tablet has been ejected from said die.

Claim 56 (previously presented). A compressed, layered pharmaceutical dosage form having its height greater than its width and configured as

a first segment comprising a composition containing an effective amount of one or more drugs (A), and

at least one additional segment comprising a composition containing an effective amount of a drug or drugs (B) or (C), and

a second segment contacting said first segment, said second segment comprising an immediate release composition substantially free of drug and forming an inner inactive segment that is adjacent above and below said first and said additional segment,

wherein said dosage form said dosage form comprises a tablet structure selected from the group consisting of A-I-B; A-I-B-I; A-I-B-I-A; A-I-B-I-B; A-I-B-I-C; and A-B-I-C wherein

“A” represents an active segment comprising a first active drug or combination of more than one active drug;

“B” represents an active segment comprising a second active drug or combination of active drugs;

“C” represents an active segment comprising a third active drug or combination of drugs; and

“I” represents an inactive segment substantially free of active drug or combination of active drugs, and

wherein the terms “height” and “width” and “above” and “below” refer to the position of said dosage form in a tablet die after tablet compression has been completed but before said tablet has been ejected from said die.

Claim 57 (previously presented). The dosage form of claim 56, wherein the compositions containing a drug or drugs, and the drug or drugs contained in said compositions are physically or chemically compatible with one another.

Claim 58 (previously presented). The dosage form of claim 56, wherein said dosage form lacks a semi-permeable membrane coating.

Claim 59 (previously presented). The dosage form of claim 56, wherein said dosage form lacks an osmotically active component to effect intrinsic altered release.

Claim 60 (previously presented). The dosage form of claim 56, wherein said dosage form lacks a drug over-coating.

Claim 61 (previously presented). The dosage form of claim 53 wherein said composition containing a drug or drugs is a controlled release composition selected from the group consisting of delayed release, modified release, sustained-release, and quick dissolve oral or buccal release.

Claim 62 (previously presented). The dosage form of claim 56 wherein said composition containing a drug or drugs is a controlled release composition selected from the group consisting of delayed release, modified release, sustained-release, and quick dissolve oral or buccal release.

Claim 63 (previously presented). The dosage form of claim 56, wherein at least one of said drug or drugs in said first segment is different than at least one of said drug or drugs in said additional segment.

Claim 64 (previously presented). The dosage form of claim 56 wherein the height of said inner segment is greater than a combined height of said first segment and said additional segment.

Claim 65 (previously presented). The dosage form of claim 56 comprising a separation mark oriented substantially horizontally on or within the inner segment to guide tablet breaking through the inner segment without breaking through the first or additional segment, said separation mark selected from the group consisting of a score, perforation, color, printed marking or indicia, and gelatin band.

Claim 66 (canceled).

Claim 67 (previously presented). The dosage form of claim 53, said dosage form comprising a separation mark positioned parallel to the vertical axis of the dosage form.

Claim 68 (previously presented). The pharmaceutical tablet of claim 53 comprising in at least one segment a colorant for visually distinguishing said segment from another segment.

Claim 69 (previously presented). The pharmaceutical tablet of claim 56 comprising in at least one segment a colorant for visually distinguishing said segment from another segment.

Claim 70 (previously presented). The dosage form of claim 56 wherein said inner segment has an effective height of at least 0.5 mm.

- 5 Claim 71 (previously presented). The dosage form of claim 70 wherein said inner segment has an effective height of about 1.5 mm to about 3 mm.

Claims 72-75 (canceled).

Claim 76 (previously presented). The dosage form of claim 53 wherein said tablet is further covered with an inert or pharmaceutically inactive composition.

- 10 Claim 77 (previously presented). The dosage form of claim 76 wherein the inert or pharmaceutically inactive composition is a capsule.

Claim 78 (previously presented). The dosage form of claim 56 wherein said tablet is further covered with an inert or pharmaceutically inactive composition.

- 15 Claim 79 (previously presented). The dosage form of claim 78 wherein the inert or pharmaceutically inactive composition is a capsule.

Claim 80 (previously presented). A compressed, layered pharmaceutical dosage form having its height greater than its width and configured as

- 20 a first segment comprising a composition containing an effective amount of one or more drugs (A), and

a second segment contacting said first segment, said second segment comprising an immediate release composition substantially free of drug and forming an inner inactive segment that is adjacent above and below said first and said additional segment,

wherein said dosage form said dosage form comprises a tablet structure selected from the group consisting of A-I-A; and A-I-A-I, wherein

- 25 "A" represents an active segment comprising a first active drug or combination of more than one active drug; and

"I" represents an inactive segment substantially free of active drug or combination of active drugs, and

- 30 wherein the terms "height" and "width" and "above" and "below" refer to the position of said dosage form in a tablet die after tablet compression has been completed but before said tablet has been ejected from said die.